Introduction: Multimorbidity is widely recognised as the presence of two or more concurrent long-term conditions, yet remains a poorly understood global issue despite increasing in prevalence.We have created the Wales Multimorbidity e-Cohort (WMC) to provide an accessible research ready data asset to further the understanding of multimorbidity. Our objectives are to create a platform to support research which would help to understand prevalence, trajectories and determinants in multimorbidity, characterise clusters that lead to highest burden on individuals and healthcare services, and evaluate and provide new multimorbidity phenotypes and algorithms to the National Health Service and research communities to support prevention, healthcare planning and the management of individuals with multimorbidity.
Methods And Analysis: The WMC has been created and derived from multisourced demographic, administrative and electronic health record data relating to the Welsh population in the Secure Anonymised Information Linkage (SAIL) Databank. The WMC consists of 2.9 million people alive and living in Wales on the 1 January 2000 with follow-up until 31 December 2019, Welsh residency break or death. Published comorbidity indices and phenotype code lists will be used to measure and conceptualise multimorbidity.Study outcomes will include: (1) a description of multimorbidity using published data phenotype algorithms/ontologies, (2) investigation of the associations between baseline demographic factors and multimorbidity, (3) identification of temporal trajectories of clusters of conditions and multimorbidity and (4) investigation of multimorbidity clusters with poor outcomes such as mortality and high healthcare service utilisation.
Ethics And Dissemination: The SAIL Databank independent Information Governance Review Panel has approved this study (SAIL Project: 0911). Study findings will be presented to policy groups, public meetings, national and international conferences, and published in peer-reviewed journals.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817800 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2020-047101 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A randomized, crossover trial of one night of oxygen therapy for obstructive sleep apnea in patients with fibrotic interstitial lung disease.
Sleep Breath
January 2025
Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Background And Objective: There is no satisfactory treatment for obstructive sleep apnea (OSA) in patients with interstitial lung disease (ILD) because of poor tolerance of positive airway pressure (PAP) therapy. Supplemental oxygen therapy has been shown to reduce hypoxemia and is well tolerated in patients with ILD. However, little is known about the effect of nocturnal oxygen supplementation (NOS) on OSA in patients with ILD.
View Article and Find Full Text PDFCurrent perspectives on the rehabilitation of COPD patients with comorbidities.
Expert Rev Respir Med
January 2025
Cardiorespiratory Rehabilitation Laboratory, University of Santa Cruz do Sul, Rio Grande do Sul, Brazil.
Introduction: Chronic obstructive pulmonary disease (COPD) is frequently accompanied by a variety of comorbidities, complicating management and rehabilitation efforts. Understanding this interplay is crucial for optimizing patient outcomes.
Areas Covered: This review, based on the MEDLINE, Embase and Cochrane Library databases, summarizes the main research on the rehabilitation of patients with COPD, with an emphasis on relevant comorbidities, such as cardiovascular diseases, pulmonary hypertension, lung cancer, metabolic, musculoskeletal, and gastrointestinal disorders.
Association Between Positive Airway Pressure Therapy and Healthcare Costs Among Older Adults with Comorbid Obstructive Sleep Apnea and Common Chronic Conditions: An Actuarial Analysis.
Sleep
January 2025
Santa Barbara Actuaries Inc., Santa Barbara, CA, USA.
Study Objectives: To determine the association between adherence to positive airway pressure and healthcare costs among a national sample of older adults with comorbid OSA and common chronic conditions.
Methods: Our data source was a random sample of Medicare administrative claims for years 2016-2019. Inclusion criteria included age >65 years and new diagnosis of OSA.
Profiles and predictors of child neurodevelopment and anthropometry: The maternal-infant research on environmental chemicals study.
J Multimorb Comorb
January 2025
Department of Epidemiology, Brown University, Providence, RI, USA.
Background: Evaluating individual health outcomes does not capture co-morbidities children experience.
Purpose: We aimed to describe profiles of child neurodevelopment and anthropometry and identify their predictors.
Methods: Using data from 501 mother-child pairs (age 3-years) in the Maternal-Infant Research on Environmental Chemicals (MIREC) Study, a prospective cohort study, we developed phenotypic profiles by applying latent profile analysis to twelve neurodevelopmental and anthropometric traits.
Research Status and Direction of Chronic Obstructive Pulmonary Disease Complicated with Coronary Heart Disease: A Bibliometric Analysis from 2005 to 2024.
Int J Chron Obstruct Pulmon Dis
January 2025
Department of Radiology, The First Affiliated Hospital of Huzhou University, Huzhou, Zhejiang, People's Republic of China.
Objective: There is increasing evidence that chronic obstructive pulmonary disease (COPD) is associated with coronary heart disease (CHD). In this study, we provide valuable insights in the field by examining the evolution of the relationship between COPD and CHD over the past 20 years.
Methods: A comprehensive computer search was conducted in the Web of Science (WOS) core dataset, covering literature on COPD combined with CHD from January 1, 2005, to August 20, 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!